For prescribing information, click here

This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience. If you are not a Healthcare Professional, please click here.
Adverse event reporting information is available at the bottom of this webpage.

Cabometyx® (Cabozantinib) therapeutic indications

Cabometyx® is indicated as monotherapy treatment of advanced renal cell carcinoma (RCC):

  • in first-line treatment of adult patients with intermediate or poor risk per IMDC criteria.
  • in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

Cabometyx® in combination with nivolumab for the first-line treatment of RCC in adults.

In this video, Anne describes how she manages her treatment and associated side effects day-by-day including specific tips, resources and how her healthcare team have supported her.

View more videos in this series by clicking the link below.

My journey with renal cell carcinoma: Diagnosis and treatment journey - from a patient's perspective

My journey with renal cell carcinoma: Diagnosis and treatment journey - from a patient's perspective

In this video, Anne describes the beginning of her journey including how she was diagnosed, when her treatment started and how her healthcare professional supported her through her journey. She also shares some top tips for people going through the same.
Watch now
Resources

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.